Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Caribou Biosciences's share price for the quarter that ended in Mar. 2026 was $1.9. Caribou Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 96.95 Mil. Therefore, Caribou Biosciences's market cap for the quarter that ended in Mar. 2026 was $184.21 Mil.
Caribou Biosciences's quarterly market cap
declined
from Sep. 2025 ($217.78 Mil) to Dec. 2025 ($151.28 Mil) but then
increased
from Dec. 2025 ($151.28 Mil) to Mar. 2026 ($184.21 Mil).
Caribou Biosciences's annual market cap
declined
from Dec. 2023 ($506.81 Mil) to Dec. 2024 ($146.88 Mil) but then
increased
from Dec. 2024 ($146.88 Mil) to Dec. 2025 ($151.28 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Caribou Biosciences's Enterprise Value for Today is $83.88 Mil.
Caribou Biosciences (NAS:CRBU) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Caribou Biosciences Market Cap Related Terms
Caribou Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Caribou Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caribou Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caribou Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Caribou Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caribou Biosciences (CRBU) has a Market Cap of $174.56 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Caribou Biosciences and its competitors. According to the industry distribution chart, Caribou Biosciences ranks #639 out of 1427 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Caribou Biosciences' Market Cap too high?
Caribou Biosciences' current Market Cap is $174.56 Mil. The Biotechnology industry median Market Cap is 119.57. Caribou Biosciences' value of $174.56 Mil is 46% above this industry median. Based on the distribution chart, Caribou Biosciences ranks #639 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Market Cap compare to YDES and PRQR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #639 out of 1427 companies for Market Cap. This puts Caribou Biosciences in the upper half of its industry. The industry median Market Cap is 119.57. Caribou Biosciences' value of $174.56 Mil is 46% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caribou Biosciences's current Market Cap of $174.56 Mil is 46% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Caribou Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Market Cap is $174.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.69, compared to a current price of $1.76 — trading 4.1% above its estimated fair value. The current Market Cap is $174.56 Mil and 46% above the Biotechnology industry median of 119.57. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Market Cap is $174.56 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caribou Biosciences (CRBU) Overvalued in 2026?
Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued.
The current stock price of $1.76 is trading 4.1% above its estimated GF Value™ of $1.69.
GuruFocus considers Caribou Biosciences to be Fairly Valued.
Key valuation signals for CRBU:
Market Cap: $174.56 Mil
GF Value™: $1.69 vs. price of $1.76 (4.1% above fair value)
Industry Position: 46% above the Biotechnology median (#639 of 1427)
No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score
Get the complete analysis for CRBU
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBU has been successfully added to your 
